Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712944 · ClinicalTrials.gov registry record · Phase 1
Testosterone Replacement in Renal Failure
A Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02712944: Clinical Trial Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
NCT02712944 is a Phase 1 study that was terminated before completion, run by Texas Tech University Health Sciences Center. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02712944, a Phase 1 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
Primary Outcome
Comparison of dose of ESA in the 2 months prior to the start of the drug and in months 5 and 6.
Interventions
- DRUG Saline
- DRUG Testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Why NCT02712944 stopped before completion
NCT02712944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02712944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02712944 about?
NCT02712944 is a clinical study titled "Testosterone Replacement in Renal Failure". The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
What is the current status of trial NCT02712944?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-07. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02712944?
The interventions under investigation include: Saline (DRUG), Testosterone (DRUG).
Who is sponsoring clinical trial NCT02712944?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02712944's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia